Annals of Hematology

, Volume 98, Issue 8, pp 1805–1812 | Cite as

Implication of HMOX1 and CCR5 genotypes on clinical phenotype of Egyptian patients with sickle cell anemia

  • Salwa BakrEmail author
  • Mervat Khorshied
  • Noha Talha
  • Karim Yahia Jaffer
  • Nohair Soliman
  • Khaled Eid
  • Mona El-Ghamrawy
Original Article


Sickle cell disease (SCD) is a relatively common inherited hemolytic anemia among individuals of African descent. Genetic factors might clarify clinical diversity of the disease and variations in treatment response. Some researchers investigated heme oxygenase-1 (HMOX1) or chemokine receptor 5 (CCR5Δ32) genotypes among SCD patients and their correlation with fetal hemoglobin (HbF) and disease severity. However, there are no such records among Arab nations. We aimed to estimate the prevalence of the HMOX1-413 A>T (rs2071746) and CCR5Δ32 (rs333) polymorphisms, and to assess their effect on SCD phenotype and HbF level among Egyptian patients. Polymerase chain reaction assay was used to determine these polymorphisms among 100 SCD patients and 100 healthy controls. Though not statistically significant, the frequency of individual carrying HMOX-1 polymorphic AT and TT genotypes in both patient and control groups was 92% and 85% respectively. Regarding CCR5Δ32 polymorphisms, all SCD patients harbored the wild genotype (100%), while the heteromutant genotype was encountered in 2% of our controls. Patients harboring mutant HMOX-1 had a less frequent vaso-occlusive crisis (VOC)/lifetime, less VOC in the last year, less incidence of stroke, less frequency of hospitalization, and responded more frequently to hydroxyurea with statistically significant differences (p = 0.028, 0.007, 0.046, 0.007, and 0.011 respectively). No significant associations with HbF level or other hematologic parameters were encountered among our cohort. Our study results suggest a protective effect of mutant HMOX-1 genotypes in ameliorating the phenotypic severity of the disease. HMOX1-413 A>T (rs2071746) polymorphisms might prove to be a prognostic marker among Egyptian SCD, but not CCR5Δ32 (rs333) polymorphisms.


Sickle cell disease HMOX1 CCR5Δ32 Egypt 


Compliance with ethical standards

The study protocol was approved by the Research Ethics Committee of Faculty of Medicine, Cairo University. Informed consents were willingly given by the parents or guardians of participants prior to enrollment in the study. All procedures performed in our study were in accordance with the 1964 Helsinki declaration.

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

277_2019_3697_MOESM1_ESM.docx (134 kb)
ESM 1 (DOCX 133 kb)


  1. 1.
    Diallo DA, Guindo A (2014) Sickle cell disease in sub-Saharan Africa: stakes and strategies for control of the disease. Curr Opin Hematol 21(3):210–214CrossRefGoogle Scholar
  2. 2.
    Bean CJ, Boulet SL, Ellingsen D, Pyle ME, Barron-Casella EA, Casella JF, Payne AB, Driggers J, Trau HA, Yang G, Jones K (2012) Heme oxygenase-1 gene promoter polymorphism is associated with reduced incidence of acute chest syndrome among children with sickle cell disease. Blood. 120(18):3822–3828CrossRefGoogle Scholar
  3. 3.
    Belcher JD, Mahaseth H, Welch TE, Otterbein LE, Hebbel RP, Vercellotti GM (2006) Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice. J Clin Invest 116(3):808–816CrossRefGoogle Scholar
  4. 4.
    Serjeant GR (1992) Sickle cell disease, 2nd edn. Oxford University Press Inc, New YorkGoogle Scholar
  5. 5.
    Chies JA, Hutz MH (2003) High frequency of the CCR5delta32 variant among individuals from an admixed Brazilian population with sickle cell anemia. Braz J Med Biol Res 36(1):71–75CrossRefGoogle Scholar
  6. 6.
    Gil GP, Ananina G, Oliveira MB, Costa FF, Silva MJ, Santos MN, Bezerra MA, Hatzlhofer BL, Araujo AS, Melo MB (2013) Polymorphism in the HMOX1 gene is associated with high levels of fetal hemoglobin in Brazilian patients with sickle cell anemia. Hemoglobin. 37(4):315–324CrossRefGoogle Scholar
  7. 7.
    Geard A, Pule GD, Chetcha Chemegni B, Ngo Bitoungui VJ, Kengne AP, Chimusa ER, Wonkam A (2017) Clinical and genetic predictors of renal dysfunctions in sickle cell anaemia in Cameroon. Br J Haematol 178(4):629–639CrossRefGoogle Scholar
  8. 8.
    Jaseb K, Ramezani A, Far MA, Mohammadi-Asl J, Khosravi A, Saki N (2017) Association between beta globin haplotypes, HBBP1 and HMOX1 polymorphisms in relation to HbF among sickle cell anemia patients: a study in Southwest Iran. Comp Clin Pathol 26(5):1149–1155CrossRefGoogle Scholar
  9. 9.
    Fertrin KY, Costa FF (2010 Aug 1) Genomic polymorphisms in sickle cell disease: implications for clinical diversity and treatment. Expert Rev Hematol 3(4):443–458CrossRefGoogle Scholar
  10. 10.
    Ono K, Mannami T, Iwai N (2003) Association of a promoter variant of the haeme oxygenase-1 gene with hypertension in women. J Hypertens 21(8):1497–1503CrossRefGoogle Scholar
  11. 11.
    Lopes MP, Santos MN, Faber EW, Bezerra MA, Hatzlhofer BL, Albuquerque DM, Zaccariotto TR, Ribeiro DM, Araújo AD, Costa FF, Sonati MD (2014) The CCR5Δ32 polymorphism in Brazilian patients with sickle cell disease. Dis Markers 2014:1–4.
  12. 12.
    Silva-Carvalho WH, de Moura RR, Coelho AV, Crovella S, Guimarães RL (2016) Frequency of the CCR5-delta32 allele in Brazilian populations: a systematic literature review and meta-analysis. Infect Genet Evol 43:101–107CrossRefGoogle Scholar
  13. 13.
    Al-Jaberi SA, Ben-Salem S, Messedi M, Ayadi F, Al-Gazali L, Ali BR (2013) Determination of the CCR5∆ 32 frequency in Emiratis and Tunisians and the screening of the CCR5 gene for novel alleles in Emiratis. Gene. 529(1):113–118CrossRefGoogle Scholar
  14. 14.
    Ghorban K, Dadmanesh M, Hassanshahi G, Momeni M, Zare-Bidaki M, Arababadi MK, Kennedy D (2013) Is the CCR5 Δ 32 mutation associated with immune system-related diseases? Inflammation. 36(3):633–642CrossRefGoogle Scholar
  15. 15.
    DÌaz F, Vega JA, PatiÒo PJ, Bedoya G, Nagles J, Villegas C, Vesga R, Rugeles MT (2000) Frequency of CCR5 ∆32 mutation in human immunodeficiency virus (HIV)-seropositive and HIV-exposed seronegative individuals and in general population of Medellin, Colombia. Mem Inst Oswaldo Cruz, Rio de Janeiro 95(2):237–242CrossRefGoogle Scholar
  16. 16.
    Hansson HH, Maretty L, Balle C, Goka BQ, Luzon E, Nkrumah FN, Schousboe ML, Rodrigues OP, Bygbjerg IC, Kurtzhals JA, Alifrangis M, Hempel C (2015) Polymorphisms in the Haem oxygenase-1promoter are not associated with severity of Plasmodium falciparum malaria in Ghanaian children. Malar J 14:153CrossRefGoogle Scholar
  17. 17.
    Stephens JC, Reich DE, Goldstein DB, Shin HD, Smith MW, Carrington M, Winkler C, Huttley GA, Allikmets R, Schriml L, Gerrard B (1998) Dating the origin of the CCR5-Δ32 AIDS-resistance allele by the coalescence of haplotypes. Am J Hum Genet 62(6):1507–1515CrossRefGoogle Scholar
  18. 18.
    Ferreira-Fernandes H, Santos AC, Motta FJ, Canalle R, Yoshioka FK, Burbano RR, Rey JA, da Silva BB, Pinto GR (2015) Prevalence of CCR5-Δ32 and CCR2-V64I polymorphisms in a mixed population from northeastern Brazil. Genet Mol Res 14(4):11710–11718CrossRefGoogle Scholar
  19. 19.
    Nascimento AF, Oliveira JS, Junior JS, Barbosa AA (2017) Haplotypes and polymorphism in the CCR5 gene in sickle cell disease. Genet Mol Res 16(2).
  20. 20.
    Vasavda N, Menzel S, Kondaveeti S, Maytham E, Awogbade M, Bannister S, Cunningham J, Eichholz A, Daniel Y, Okpala I, Fulford T (2007) The linear effects of α-thalassaemia, the UGT1A1 and HMOX1 polymorphisms on cholelithiasis in sickle cell disease. Br J Haematol 138(2):263–270CrossRefGoogle Scholar
  21. 21.
    Wagener FA, da Silva JL, Farley T, de Witte T, Kappas A, Abraham NG (1999) Differential effects of heme oxygenase isoforms on heme mediation of endothelial intracellular adhesion molecule 1 expression. J Pharmacol Exp Ther 291(1):416–423Google Scholar
  22. 22.
    Wagener FA, Eggert A, Boerman OC, Oyen WJ, Verhofstad A, Abraham NG, Adema G, van Kooyk Y, de Witte T, Figdor CG (2001) Heme is a potent inducer of inflammation in mice and is counteracted by heme oxygenase. Blood. 98(6):1802–1811CrossRefGoogle Scholar
  23. 23.
    Soares MP, Seldon MP, Gregoire IP, Vassilevskaia T, Berberat PO, Yu J, Tsui TY, Bach FH (2004) Heme oxygenase-1 modulates the expression of adhesion molecules associated with endothelial cell activation. J Immunol 172(6):3553–3563CrossRefGoogle Scholar
  24. 24.
    Evans C, Orf K, Horvath E, Levin M, De La Fuente J, Chakravorty S, Cunnington AJ (2015) Impairment of neutrophil oxidative burst in children with sickle cell disease is associated with heme oxygenase-1. haematologica. 100(12):1508–1516CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Clinical Pathology/Hematology, Faculty of MedicineFayoum UniversityFaiyumEgypt
  2. 2.Imam Abdulrahman Bin Faisal UniversityDammamSaudi Arabia
  3. 3.Department of Clinical & Chemical Pathology, Faculty of MedicineCairo UniversityCairoEgypt
  4. 4.Department of Pediatric, Pediatric Hematology and BMT Unit, Faculty of MedicineCairo UniversityCairoEgypt
  5. 5.College of MedicineAin Shams UniversityCairoEgypt

Personalised recommendations